Apellis Pharmaceuticals, Inc.
Apellis Pharmaceuticals, Inc. (APLS): 14 pipeline candidates · 5 upcoming catalysts · ~29 mo cash runway · 16 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
29.2 months
D/E 1.61 · 3% dilution
Lead: Approved
14 candidates
5 upcoming, next in ~378d
0 buys · 25 sells (180d)
A transparent, data-derived signal for Apellis Pharmaceuticals, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$5.3B
Cash
$406.7M
Quarterly Burn
$61.0M
Runway
29.2 mo
Revenue
$268.3M
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (14 candidates)
| Drug | Phase |
|---|---|
| APL-2, Pegcetacoplan | Phase 3 |
| APL-3007 | Phase 2 |
| APL-3007, pegcetacoplan | Phase 3 |
| APL-9099 | Preclinical |
| APL2 | Phase 2/Phase 3 |
| Aspaveli | Approved |
| Base editing therapies (C3 and complement targets) | Preclinical |
| EMPAVELI | Approved |
| FcRn targeting gene editing treatment | Preclinical |
| Oral complement inhibitor | Preclinical |
Showing 10 of 14 candidates. Sign up for full pipeline.
Upcoming Catalysts (5)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
325
Total value held
$5.53B
| Holder | Shares | Value |
|---|---|---|
| blackrock, inc. | 13,536,964 | $544.6M |
| avoro capital advisors llc | 12,222,222 | $491.7M |
| morgan stanley | 10,042,399 | $404.0M |
| vanguard capital management llc | 9,537,888 | $383.7M |
| state street corp | 6,844,990 | $275.4M |
| vanguard portfolio management llc | 5,404,559 | $217.4M |
| pentwater capital management lp | 5,250,000 | $211.2M |
| deep track capital, lp | 4,532,374 | $182.3M |
| point72 asset management, l.p. | 4,183,918 | $168.3M |
| rtw investments, lp | 3,685,045 | $148.2M |
Showing top 10 of 325 institutional holders of Apellis Pharmaceuticals, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Apellis Pharmaceuticals, Inc.'s pipeline?
Apellis Pharmaceuticals, Inc. (APLS) has 14 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Apellis Pharmaceuticals, Inc.'s lead drug candidate?
Apellis Pharmaceuticals, Inc.'s most advanced tracked candidate is APL-2, Pegcetacoplan (Phase 3) for Geographic Atrophy Secondary to Age-related Macular Degeneration.
What is Apellis Pharmaceuticals, Inc.'s next catalyst?
Apellis Pharmaceuticals, Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Effic" — expected July 1, 2027.
What is Apellis Pharmaceuticals, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Apellis Pharmaceuticals, Inc. has approximately 29.2 months of cash runway.
What is Apellis Pharmaceuticals, Inc.'s market capitalization?
Apellis Pharmaceuticals, Inc.'s market capitalization is approximately $5.3B.
Get the full picture on Apellis Pharmaceuticals, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.